Navigation Links
Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
Date:1/5/2009

KING OF PRUSSIA, Pa., Jan. 5 /PRNewswire/ -- Prism Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) has approved the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone(R) Intravenous. NEXTERONE is indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.

"Approval of our first product is an important corporate milestone and validates our accelerated development model, which allowed us to move NEXTERONE from licensing to FDA clearance in less than three years and ahead of the PDUFA target date," said Dr. Warren D. Cooper, President and CEO of Prism. "We developed NEXTERONE to overcome solvent-based limitations of conventional intravenous amiodarone and to improve patient care and overall medication management in the setting of life-threatening cardiac arrhythmias."

NEXTERONE represents the first product to successfully overcome the long recognized solubility issues of amiodarone by removing the original cosolvents polysorbate 80 and benzyl alcohol. As a result of removing these cosolvents, NEXTERONE does not have many of the product administration limitations regarding compatibility and stability with plastics and ionic infusion fluids, which are included in the labeling of conventional intravenous amiodarone. Importantly, NEXTERONE does not carry the specific warning about the risk of fatal gasping syndrome in newborn infants because it does not contain benzyl alcohol.

Improving medication safety in the hospital environment is an area of significant and current attention. This agenda is being driven by entities such as The Joint Commission, which is responsible
'/>"/>

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... LAUREL, N.J., July 1 MedQuist Inc.,(Pink ... community hospital,located in Westfield, Mass., has selected ... to provide hospital-wide,dictation, transcription and speech recognition ... recognition capability will be,used throughout the hospital ...
... and Bruce Bradley (General,Motors) - to Serve as ... ABIM Foundation,will dedicate its efforts over the next ... and accountability in health care toward the,ultimate goal ... Foundation announced that officers of its Board of,Trustees ...
... WALTHAM, Mass., July 1 Repligen Corporation,(Nasdaq: RGEN ... has been,elected to its Board of Directors. Dr. Goldberg ... School. He is a renowned scientist noted in,particular for ... the mechanism by which most proteins are destroyed in,cells. ...
... fed junk food had higher cholesterol, blood fats into ... News) -- Eating an unhealthy diet during pregnancy may ... cholesterol and blood sugar levels, British researchers report. , ... fed one group of females a diet of processed ...
... Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical ... ... Resources, WALTHAM, Mass., July 1 ... on pharmaceutical and,healthcare issues, finds that a weight neutral oral antidiabetic drug ...
... Health Administrator, Meet Aggressive Hospital Opening Schedule; Eases Ongoing IT ... ... Effort, RIOJA, Spain, July 1 TIBCO Software Inc.,(Nasdaq: ... region of Rioja has deployed its real-time integration,infrastructure. The project at ...
Cached Medicine News:Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 2Health News:Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition 3Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2Health News:A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market 2Health News:Rioja Hospital Uses TIBCO Software to Improve Customer Care and Streamline Operations 2
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014  Novation, the leading health care supply ... IT value-added reseller (VAR) national contracts that expand its ... services at lower costs. These include manufacturer product and ... initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... a Conference Call on Monday, April 14, at 8:30 a.m. E.T. ... ... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced additional results from its,ongoing ... hypercholesterolemia (FH). In FH patients exposed to,mipomersen for as long as ...
... Researchers from the,Barbara Ann Karmanos Cancer ... adding curcumin or resveratrol to conventional chemotherapy,could ... chemo-resistant colon cancer,cells. The poster presentation was ... (AACR) Annual Meeting in San Diego, CA., ...
Cached Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
... Supplemental Confirmatory (Western Blot): The assay uses ... on their surface. The cells are fixed ... slide. Fixed, uninfected T-cells are provided as ... sample with HIV- I antibodies comes in ...
Bi-phasic peristaltic infusion pump for tumescent work....
... The Klein Pump provides ... requiring tumescent infiltration. Operates on ... off switch with safety Interlock ... Single Spike Tubing, Double Spike ...
... state of the art Aspirator offers ... It can accommodate up to 5 ... eliminating time consuming canister changes. The ... powerful performance with minimal noise. It ...
Medicine Products: